Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.16441 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identifying prognostic gene panels in acute myeloid leukemia.
Expert Rev Hematol
April 2023
Hematology-Department, University Hospital La Fe, Valencia, Spain.
Introduction: Acute myeloid leukemia (AML) is a heterogeneous disease currently including 12 entities defined by genetic findings with remarkable differences in prognosis and targeted therapies availability. Therefore, identification of genetic abnormalities by efficient techniques has become a necessary tool in routine clinical practice for AML patients.
Areas Covered: In the present review, we will focus on our current knowledge of relevant prognosis gene mutations in AML, as recently updated by European Leukemia Net Leukemia risk classification.
Treatment of myelodysplasia-associated reactive, non-interstitial granulomatous dermatitis with hydroxychloroquine.
Int J Dermatol
July 2023
Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA.
Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
Haematologica
October 2012
Servicio General de Citometría and Department of Medicine, Universidad de Salamanca, Spain.
Increased risk of acute myeloid leukemia/myelodysplastic syndromes following treatment has been reported in multiple myeloma, but whether dysplastic features are already present at diagnosis remains to be investigated. Using multiparameter flow cytometry, we analyzed the distribution and phenotype of bone marrow hematopoietic cells from 47 multiple myeloma patients (15 symptomatic and 32 high-risk smoldering). From the 32 smoldering myeloma patients, 18 were studied at baseline and 22 after nine cycles of lenalidomide/dexamethasone treatment following the QUIREDEX trial (including 8 from baseline).
View Article and Find Full Text PDFFamilial myelodysplastic syndromes: a review of the literature.
Haematologica
October 2011
Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Familial cases of myelodysplastic syndromes are rare, but are immensely valuable for the investigation of the molecular pathogenesis of myelodysplasia in general. The best-characterized familial myelodysplastic syndrome is that of familial platelet disorder with propensity to myeloid malignancy, caused by heterozygous germline RUNX1 mutations. Recently, there has been an increase in the number of reported cases, allowing for better understanding of the incidence, clinical features, and pathogenesis of this disorder.
View Article and Find Full Text PDFAcute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report.
J Med Case Rep
August 2010
Section of Medical Oncology, The Aga Khan University Hospital, Karachi, Pakistan.
Introduction: We report the development of acute lymphoblastic leukemia in a patient in whom temozolomide was used for the treatment of a brain tumor. Unlike that of other alkylating agents, the leukemogenic potential of temozolomide is considered to be very low, and very rarely are such cases reported.
Case Presentation: A 26-year-old Pakistani man who was treated for glioblastoma with temozolomide in an adjuvant setting was diagnosed to have acute lymphoblastic leukemia one year after stopping temozolomide.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!